Preoperative HFRT Verses PULSAR for Locally Advanced GEJ or Proximal Gastric Adenocarcinoma

Last updated: December 8, 2024
Sponsor: Fudan University
Overall Status: Active - Recruiting

Phase

2

Condition

Gastric Cancer

Stomach Cancer

Adenocarcinoma

Treatment

R0 total/subtotal gastrectomy with D2 lymphadenectomy

Anti-PD-1 monoclonal antibody

PULSAR targeted to the primary lesion and positive lymph nodes

Clinical Study ID

NCT06728657
FDRT-2024-251-3805
  • Ages 18-75
  • All Genders

Study Summary

The goal of this clinical trial is to evaluate the efficacy and safety of the multimodal treatment, which includes radiotherapy, chemotherapy and anti-PD-1 immunotherapy. The trial is designed using a pick-the-winner strategy.

The main questions it aims to answer are:

  1. If the multimodal treatment will improve the pCR rate.

  2. If the multimodal treatment can be performed safely.

  3. Hypofractionated radiotherapy (HFRT) or personalized hyperfractionated stereotactic adaptive radiotherapy (PULSAR), which pattern of radiotherapy can better synergize with immunotherapy.

Participants will receive HFRT or PULSAR for the primary lesion and positive lymph nodes, combined with CAPOX and anti-PD-1 immunotherapy. Then, reassessment will be performed within 4 weeks afterwards. For resectable participants, surgical resections will be performed. Postoperative treatment will be determined by the investigators. For unresectable or inoperable participants, the subsequent treatment will be determined by investigators or MDT.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Histopathologically confirmed adenocarcinoma of proximal stomach (G) orgastroesophageal junction (GEJ) (excluding Siewert type I).

  • Potentially resectable, cT3-4aN+M0 or cT4bNanyM0.

  • Exclusion of peritoneal metastasis through laparoscopic exploration or FAPI PET/CT.

  • The status of HER2, MMR, EBER is clear.

  • Male or female. Patient age ≥ 18 years and ≤ 75 years.

  • Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) score of 0 or 1.

  • Physical state or organ function can tolerate the planned treatment of the studyprotocol.

  • No previous surgery or antitumor therapies, including chemotherapy, radiotherapy, orimmunotherapy, were administered.

  • Patients agree to sign written informed consent before recruitment.

Exclusion

Exclusion Criteria:

  • Pregnancy or breastfeeding women.

  • History of other malignancies within 5 years.

  • Serious medical illness, such as severe mental disorders, cardiac disease,uncontrolled infection, etc.

  • Immunodeficiency disease or long-term using of immunosuppressive agents.

  • Allergic to any component of the therapy.

  • Any other condition or disease that is not suitable to take the therapy included inthe protocol.

Study Design

Total Participants: 68
Treatment Group(s): 5
Primary Treatment: R0 total/subtotal gastrectomy with D2 lymphadenectomy
Phase: 2
Study Start date:
July 01, 2024
Estimated Completion Date:
December 31, 2028

Connect with a study center

  • Fudan University Shanghai Cancer Center

    Shanghai, 200032
    China

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.